STOCK TITAN
  1. Home
  2. News
  3. MEIP

MEI Pharma Inc - MEIP STOCK NEWS

Welcome to our dedicated news page for MEI Pharma (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEI Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEI Pharma's position in the market.

News
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the special meeting on July 23, 2023. Independent leading proxy advisory firms ISS and Glass Lewis recommend shareholders vote FOR the transaction. The combined company is well capitalized to advance three differentiated clinical-stage therapeutic development pipelines, creating opportunities for shareholders to benefit from near-term value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
News
MEI Pharma Responds to Anson and Cable Car
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP): Response to Consent Solicitation by Anson Advisors Inc. and Cable Car Capital LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
-
News
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
Rhea-AI Summary
MEI Pharma encourages shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, creating a combined company with a diversified pipeline of three clinical-stage development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
MEI Pharma Postpones Special Meeting of Shareholders
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) has postponed its special meeting with Infinity Pharmaceuticals, Inc. to July 23, 2023. Leading proxy advisory firms ISS and Glass Lewis recommend MEI shareholders vote for the transaction. MEI shareholders have an opportunity to participate in a well-capitalized combined company with a diversified pipeline of three clinical-stage development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
none
-
News
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
Rhea-AI Summary
MEI Pharma, Inc. (NASDAQ: MEIP) reminds shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) in connection with the upcoming special meeting on July 14, 2023. Leading proxy advisory firms, ISS and Glass Lewis, recommend MEI shareholders vote FOR the Infinity transaction, recognizing its strategic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
acquisition
-
News
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
Rhea-AI Summary
Glass Lewis and ISS recommend MEI Pharma shareholders to vote for the Infinity transaction. MEI Pharma encourages shareholders to follow the recommendations and highlights the potential benefits of the combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
acquisition
News
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
News
MEI Pharma Responds to Anson and Cable Car
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
News
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
acquisition
Stock MEIP logo
MEI Pharma Inc

Nasdaq:MEIP

MEIP Rankings

#5137 Ranked by Market Cap
#1883 Ranked by Stock Gains
N/A Ranked by Dividends

MEIP Stock Data

21.79M
4.94M
0.54%
47.58%
0.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MEIP

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.